Advanced

Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort

Persson, Mia; Simonsson, Maria LU ; Markkula, Andrea LU ; Rose, Carsten LU ; Ingvar, Christian LU and Jernström, Helena LU (2016) In British Journal of Cancer 115(3). p.382-390
Abstract

Background:The association between smoking and breast cancer prognosis remains unclear. The purpose of this study was to investigate whether preoperative smoking was associated with prognosis in different treatment groups.Methods:This population-based cohort consisted of 1065 breast cancer patients without preoperative treatment included between 2002 and 2012 in Lund, Sweden. Smoking status was examined in relation to patient and tumour characteristics, and prognosis in different treatment groups.Results:At the preoperative visit, 21.0% smoked. Median follow-up time was 5.1 years. Overall, in the 1016 patients included in the survival analyses, there was no significant association between smoking and risk of breast cancer events... (More)

Background:The association between smoking and breast cancer prognosis remains unclear. The purpose of this study was to investigate whether preoperative smoking was associated with prognosis in different treatment groups.Methods:This population-based cohort consisted of 1065 breast cancer patients without preoperative treatment included between 2002 and 2012 in Lund, Sweden. Smoking status was examined in relation to patient and tumour characteristics, and prognosis in different treatment groups.Results:At the preoperative visit, 21.0% smoked. Median follow-up time was 5.1 years. Overall, in the 1016 patients included in the survival analyses, there was no significant association between smoking and risk of breast cancer events (adjusted hazard ratio (adjHR): 1.45; 95% confidence interval (CI): 0.95–2.20). For the 309 aromatase inhibitor (AI)-treated patients ⩾50 years with oestrogen receptor-positive (ER+) tumours, smoking was associated with risk of breast cancer events (adjHR: 2.97; 95% CI: 1.44–6.13), distant metastasis (adjHR: 4.19; 95% CI: 1.81–9.72), and death (adjHR: 3.52; 95% CI: 1.59–7.81). Smoking was not associated with breast cancer events or distant metastasis in other treatment groups.Conclusions:Preoperative smoking was only associated with an increased risk for breast cancer events and distant metastasis in AI-treated patients. If confirmed, smoking status should be taken into consideration when selecting an endocrine therapy.British Journal of Cancer advance online publication, 9 June 2016; doi:10.1038/bjc.2016.174 www.bjcancer.com.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Cancer
volume
115
issue
3
pages
382 - 390
publisher
Nature Publishing Group
external identifiers
  • Scopus:84973624942
  • WOS:000380380400015
ISSN
0007-0920
DOI
10.1038/bjc.2016.174
language
English
LU publication?
yes
id
083afac2-58c6-4443-bd6d-a479f99ba824
date added to LUP
2016-06-23 07:47:58
date last changed
2017-01-01 08:28:49
@article{083afac2-58c6-4443-bd6d-a479f99ba824,
  abstract     = {<p>Background:The association between smoking and breast cancer prognosis remains unclear. The purpose of this study was to investigate whether preoperative smoking was associated with prognosis in different treatment groups.Methods:This population-based cohort consisted of 1065 breast cancer patients without preoperative treatment included between 2002 and 2012 in Lund, Sweden. Smoking status was examined in relation to patient and tumour characteristics, and prognosis in different treatment groups.Results:At the preoperative visit, 21.0% smoked. Median follow-up time was 5.1 years. Overall, in the 1016 patients included in the survival analyses, there was no significant association between smoking and risk of breast cancer events (adjusted hazard ratio (adjHR): 1.45; 95% confidence interval (CI): 0.95–2.20). For the 309 aromatase inhibitor (AI)-treated patients ⩾50 years with oestrogen receptor-positive (ER+) tumours, smoking was associated with risk of breast cancer events (adjHR: 2.97; 95% CI: 1.44–6.13), distant metastasis (adjHR: 4.19; 95% CI: 1.81–9.72), and death (adjHR: 3.52; 95% CI: 1.59–7.81). Smoking was not associated with breast cancer events or distant metastasis in other treatment groups.Conclusions:Preoperative smoking was only associated with an increased risk for breast cancer events and distant metastasis in AI-treated patients. If confirmed, smoking status should be taken into consideration when selecting an endocrine therapy.British Journal of Cancer advance online publication, 9 June 2016; doi:10.1038/bjc.2016.174 www.bjcancer.com.</p>},
  author       = {Persson, Mia and Simonsson, Maria and Markkula, Andrea and Rose, Carsten and Ingvar, Christian and Jernström, Helena},
  issn         = {0007-0920},
  language     = {eng},
  number       = {3},
  pages        = {382--390},
  publisher    = {Nature Publishing Group},
  series       = {British Journal of Cancer},
  title        = {Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort},
  url          = {http://dx.doi.org/10.1038/bjc.2016.174},
  volume       = {115},
  year         = {2016},
}